Selzentry (Maraviroc, Celsentri)
| Brand Name: |
Selzentry |
| Generic Name: |
Maraviroc, MVC |
| Adult Single Dose*: |
One 300 mg tablet twice daily |
| Food & Liquid Restrictions: |
None. |
| Drug Class: |
Entry Inhibitor |
|
|
|
READ FIRST:
- An Overview of Selzentry (Maraviroc, Celsentri) (November 23, 2008)
To read PDF, click here
From U.S. National Institutes of Health
- A Revolutionary New Way to Fight HIV/AIDS: CCR5 Inhibitors (September 2008)
Find out more about Selzentry in this special report.
From The Body
- Maraviroc (Selzentry, Celsentri) (December 4, 2008)
To read PDF, click here
From AIDS InfoNet
- A New Way to Fight HIV: CCR5 Inhibitors (April 30, 2008)
An interview with David Hardy, M.D.
From The Body
- Selzentry (March/April 2009)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- The Basics on Maraviroc: An Interview With Joel Gallant, M.D., M.P.H. (August 6, 2007)
From The Body
The Basics
- Characteristics of Fusion and Integrase Inhibitors, and CCR5 Antagonists (PDF) (November 3, 2008)
An excerpt from the official U.S. HIV treatment guidelines for adults and adolescents. For the full guidelines, click here (PDF).
From AIDSinfo
- Patient Information About Selzentry (Maraviroc, Celsentri) (PDF) (November 2008)
From Pfizer, Inc.
- Selzentry (Maraviroc) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- FDA Approves Pfizer's Antiretroviral Maraviroc (August 7, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Approval of Maraviroc (August 6, 2007)
From U.S. Food and Drug Administration
- CCR5: A Genetic Mistake Makes Good (March 2004)
[Archived Article]
From amfAR, The Foundation for AIDS Research
|
|
Advertisement
|
E-Mail
Glossary
Share
